期刊文献+

新型吗啉-查尔酮类衍生物的设计合成及体外抗宫颈癌活性

Design,Synthesis,and In Vitro Anti-cervical Cancer Activity Testing of Novel Morpholine Chalcone Derivatives
在线阅读 下载PDF
导出
摘要 查尔酮属于类黄酮类化合物,它们的天然化合物或合成类似物具有广泛的抗癌活性。本文基于反式-查尔酮的结构,采用药效团拼合原理设计了一系列新型吗啉-查尔酮类衍生物,作为抗宫颈癌的潜在药物,其中包括8个新型查尔酮类衍生物(2a~2h),通过克莱森-施密特反应合成化合物2a~2h,通过^(1)H NMR、^(13)C NMR、HR-MS(ESI)进行结构表征。选用人宫颈癌细胞(HeLa、SiHa、C33-A)和人宫颈正常细胞(H8)为体外模型,采用CCK-8法测定了目标化合物的抗增殖活性,选出候选化合物,并通过分子对接技术研究候选化合物对鼠双微体2(MDM2)蛋白的结合能力。结果表明:大部分化合物对宫颈癌细胞有不同程度的抗增殖活性,其中化合物2a的活性较为突出,对HeLa细胞的IC_(50)值为17.25±0.06μmol/L,优于先导化合物和顺铂;化合物2a对人宫颈正常细胞(H8)毒性较低,IC_(50)值为78.70±1.91μmol/L。分子对接结果表明:化合物2a能较好地与MDM2蛋白结合。 Chalcone belongs to the flavonoid class of compounds,and their natural compounds or synthetic analogues have a wide range of anticancer activities.This article is based on the structure of trans chalcone and uses the principle of pharmacophore assembly to design a series of novel morpholine chalcone derivatives as potential drugs for the treatment of cervical cancer,including 8 novel chalcone derivatives(2a~2h).Compounds 2a~2h were synthesized through the Claisen Schmidt reaction and analyzed by ^(1)H NMR,^(13)C NMR and HR-MS(ESI)was used for structural characterization.Human cervical cancer cells(HeLa,SiHa,C33-A)and human normal cervical cells(H8)were selected as in vitro models.The anti proliferative activity of the target compound was determined using the CCK-8 method,and candidate compounds were selected.The binding ability of the candidate compounds to MDM2 protein in mice was studied using molecular docking technology.The results showed that most compounds had varying degrees of anti proliferative activity against cervical cancer cells,with compound 2a showing more prominent activity.The IC_(50)value for HeLa cells was 17.25±0.06μmol/L,which was superior to the lead compound and cisplatin;Compound 2a has low toxicity to human cervical normal cells(H8),with an IC_(50)value of 78.70±1.91μmol/L.The molecular docking results indicate that compound 2a can bind well to MDM2 protein.
作者 邓欣怡 侯代亮 海尼木·夏木西 木合布力·阿布力孜 DENG Xinyi;HOU Dailiang;Hainimu XIAMUXI;Mourboul ABLISE(College of Pharmacy,Xinjiang Medical University,Urumqi 830011,China)
出处 《合成化学》 2026年第3期159-165,共7页 Chinese Journal of Synthetic Chemistry
基金 19期大学生创新训练计划项目(S202410760042) 新疆医科大学博士科研启动基金项目(2019-16)。
关键词 查尔酮 药物分子设计 化学合成 宫颈癌 MDM2蛋白 chalcone drug molecular design chemical synthesis cervical carcinoma MDM2 protein
  • 相关文献

参考文献10

二级参考文献37

  • 1玉苏普瓦吉木·阿力木江,艾孜提艾力·艾海提,木合布力·阿布力孜,杨争,赛力克阿拉·阿里汗,刘正叶.新型三氟甲基查耳酮类衍生物的设计、合成及体外抗宫颈癌活性[J].中国药科大学学报,2022,53(6):674-684. 被引量:4
  • 2顾宏霞,张强,包贝贝,何黎琴,吴虹.丹皮酚查尔酮衍生物的合成及抗肿瘤活性[J].商丘师范学院学报,2023,39(6):28-30. 被引量:2
  • 3刘俊丽,陈元,蔡煜.表皮生长因子受体酪氨酸激酶抑制剂ZD1839对宫颈癌细胞的作用[J].肿瘤防治研究,2006,33(7):512-515. 被引量:1
  • 4[1]ShenLF,ChenA,TsengHH,et al.Experession of p53 proteininnasopharyngealcarcinoma[J].JPathol,1994,172:294.
  • 5[2]Oliner JD,Kinzler KW,Meltzer PS,et al.Amplification of a gene encoding a p53-associated protein in human sarcomas[J].Nature,1992,358(6 381):80-83.
  • 6[3]Meltzer PS.MDM2 and p53:aquestion of balance[J].JNatl Cancerl nst,1994,86(17):1 265-1 266.
  • 7[4]Mom and J,Zam betti GP.MDM2:"big brother"of p53[J].JCell Biochem,1997,64(3):343-352.
  • 8[5]HauptY,MayaR,KazazA,et al.MDM2promotes the rapid degradation of p53[J].Nature,1997,387:296-299.
  • 9[6]Kessis TD,Slebos RJ,Han SM,et al.p53 gene mutations and MDM2amplification are uncommonin primary carcinomas of the uterine cervix[J].Am J Pathol,1993 Nov;143(5):405-1 398.
  • 10[7]Ikenberg H,Matthay K,Schmitt B,et al.p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas[J].Cancer 1995,76(1):57-66.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部